Advertisement
Canada markets open in 3 hours 14 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7311
    -0.0010 (-0.13%)
     

  • CRUDE OIL

    82.98
    -0.38 (-0.46%)
     

  • Bitcoin CAD

    90,738.77
    +234.62 (+0.26%)
     

  • CMC Crypto 200

    1,432.14
    +8.04 (+0.56%)
     

  • GOLD FUTURES

    2,329.50
    -12.60 (-0.54%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,691.50
    +84.75 (+0.48%)
     

  • VOLATILITY

    15.89
    +0.20 (+1.27%)
     

  • FTSE

    8,088.15
    +43.34 (+0.54%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6837
    +0.0001 (+0.01%)
     

Celldex to Participate in Upcoming November Investor Conferences

Celldex Therapeutics, Inc.
·1 min read
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:

  • Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ET

  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMT

  • Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

ADVERTISEMENT

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com